the issue is the 'larger than usual' references the usage of its inMotion platform, and unless they have a different arrangement with other users (to the one they recently signed with this 10k pharmacy group), it makes no immediate impact to revenues.....it seems to be purely a platform to reach more users which then makes their sales pitch to pharma companies easier to sell.......a few too many loops IMO for them to jump when that end sale is so discretionary
the better option would be what they have in Aus by charging for the software, and then also selling that patient reach to pharma companies......although even Aus is barely breakeven with this approach
as I said in my earlier post, it seems like MDR shareholders are paying upfront for them to build this platform and attract users and HOPING that they can then attract pharma companies with their digital reach.......has not worked for years and time for the model to change
Add to My Watchlist
What is My Watchlist?
